Anti-MAG IgM: differences in antibody tests and correlation with clinical findings

Sabrina Matà, Stefano Ambrosini, Domenica Saccomanno, Tiziana Biagioli, Marinella Carpo, Aldo Amantini, Fabio Giannini, Alessandro Barilaro, Lucia Toscani, Monica Del Mastio, Giacomo Pietro Comi, Sandro Sorbi

Research output: Contribution to journalArticle

Abstract

Objectives: Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests’ results. Methods: Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA. Results: Among 40 anti-MAG EIA positive sera, 85% also had anti-PNM IFA reactivity and 67.5% bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy. Conclusion: Different methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.

Original languageEnglish
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Myelin-Associated Glycoprotein
Immunoglobulin M
Myelin Sheath
Antibodies
Peripheral Nerves
Fluorescent Antibody Technique
Sulfoglycosphingolipids
Polyneuropathies
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Serum
Haplorhini
Anti-Idiotypic Antibodies
Cohort Studies
Western Blotting
Phenotype

Keywords

  • Autoimmune diseases
  • Chronic inflammatory demyelinating polyneuropathy
  • EMG
  • HNK-1
  • Myelin-associated glycoprotein

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Anti-MAG IgM : differences in antibody tests and correlation with clinical findings. / Matà, Sabrina; Ambrosini, Stefano; Saccomanno, Domenica; Biagioli, Tiziana; Carpo, Marinella; Amantini, Aldo; Giannini, Fabio; Barilaro, Alessandro; Toscani, Lucia; Del Mastio, Monica; Comi, Giacomo Pietro; Sorbi, Sandro.

In: Neurological Sciences, 01.01.2019.

Research output: Contribution to journalArticle

Matà, S, Ambrosini, S, Saccomanno, D, Biagioli, T, Carpo, M, Amantini, A, Giannini, F, Barilaro, A, Toscani, L, Del Mastio, M, Comi, GP & Sorbi, S 2019, 'Anti-MAG IgM: differences in antibody tests and correlation with clinical findings', Neurological Sciences. https://doi.org/10.1007/s10072-019-04089-7
Matà, Sabrina ; Ambrosini, Stefano ; Saccomanno, Domenica ; Biagioli, Tiziana ; Carpo, Marinella ; Amantini, Aldo ; Giannini, Fabio ; Barilaro, Alessandro ; Toscani, Lucia ; Del Mastio, Monica ; Comi, Giacomo Pietro ; Sorbi, Sandro. / Anti-MAG IgM : differences in antibody tests and correlation with clinical findings. In: Neurological Sciences. 2019.
@article{e882afc418814a82bc8f59450e99fd2b,
title = "Anti-MAG IgM: differences in antibody tests and correlation with clinical findings",
abstract = "Objectives: Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests’ results. Methods: Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA. Results: Among 40 anti-MAG EIA positive sera, 85{\%} also had anti-PNM IFA reactivity and 67.5{\%} bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy. Conclusion: Different methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.",
keywords = "Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy, EMG, HNK-1, Myelin-associated glycoprotein",
author = "Sabrina Mat{\`a} and Stefano Ambrosini and Domenica Saccomanno and Tiziana Biagioli and Marinella Carpo and Aldo Amantini and Fabio Giannini and Alessandro Barilaro and Lucia Toscani and {Del Mastio}, Monica and Comi, {Giacomo Pietro} and Sandro Sorbi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10072-019-04089-7",
language = "English",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Anti-MAG IgM

T2 - differences in antibody tests and correlation with clinical findings

AU - Matà, Sabrina

AU - Ambrosini, Stefano

AU - Saccomanno, Domenica

AU - Biagioli, Tiziana

AU - Carpo, Marinella

AU - Amantini, Aldo

AU - Giannini, Fabio

AU - Barilaro, Alessandro

AU - Toscani, Lucia

AU - Del Mastio, Monica

AU - Comi, Giacomo Pietro

AU - Sorbi, Sandro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests’ results. Methods: Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA. Results: Among 40 anti-MAG EIA positive sera, 85% also had anti-PNM IFA reactivity and 67.5% bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy. Conclusion: Different methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.

AB - Objectives: Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests’ results. Methods: Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA. Results: Among 40 anti-MAG EIA positive sera, 85% also had anti-PNM IFA reactivity and 67.5% bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy. Conclusion: Different methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.

KW - Autoimmune diseases

KW - Chronic inflammatory demyelinating polyneuropathy

KW - EMG

KW - HNK-1

KW - Myelin-associated glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=85074410280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074410280&partnerID=8YFLogxK

U2 - 10.1007/s10072-019-04089-7

DO - 10.1007/s10072-019-04089-7

M3 - Article

C2 - 31654362

AN - SCOPUS:85074410280

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -